ArticleNucleic acids research2005
Specific binding of the methyl binding domain protein 2 at the BRCA1-NBR2 locus.
Article in Nucleic acids research, 2005. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 34 citations in OpenAlex.
- Article
- Notch-associated lncRNAs profiling circuiting epigenetic modification in colorectal cancer.Cancer cell international · 2022Review
- Pan-Cancer Analysis Reveals the Prognostic Potential of the THAP9/THAP9-AS1 Sense-Antisense Gene Pair in Human Cancers.Non-coding RNA · 2022Article
- Article
- Long Non-Coding RNA Neighbor of BRCA1 Gene 2: A Crucial Regulator in Cancer Biology.Frontiers in oncology · 2021Review
- DNA methylation signal has a major role in the response of human breast cancer cells to the microenvironment.Oncogenesis · 2017Article
- Methyl-CpG-binding protein MBD2 plays a key role in maintenance and spread of DNA methylation at CpG islands and shores in cancer.Oncogene · 2017Article
- MBD2 as a novel marker associated with poor survival of patients with hepatocellular carcinoma after hepatic resection.Molecular medicine reports · 2016Article
- Inhibition of DNA methylation promotes breast tumor sensitivity to netrin-1 interference.EMBO molecular medicine · 2016Article
- Tagging methyl-CpG-binding domain proteins reveals different spatiotemporal expression and supports distinct functions.Epigenomics · 2016Article
- Emerging Molecular and Biological Functions of MBD2, a Reader of DNA Methylation.Frontiers in genetics · 2016Review
- Dynamics of MBD2 deposition across methylated DNA regions during malignant transformation of human mammary epithelial cells.Nucleic acids research · 2015Article
- Structure and function insights into the NuRD chromatin remodeling complex.Cellular and molecular life sciences : CMLS · 2015Review
- TP63 P2 promoter functional analysis identifies β-catenin as a key regulator of ΔNp63 expression.Oncogene · 2011Article
- A role for methyl-CpG binding domain protein 2 in the modulation of the estrogen response of pS2/TFF1 gene.PloS one · 2010Article
- MBD2 is required for correct spatial gene expression in the gut.Molecular and cellular biology · 2007Article
- Aberrant promoter methylation of the ABCG2 gene in renal carcinoma.Molecular and cellular biology · 2006Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The methyl-CpG binding domain (MBD) proteins are key molecules in the interpretation of DNA methylation signals leading to gene silencing. We investigated their binding specificity at the constitutively methylated region of a CpG island containing the bidirectional promoter of the Breast cancer predisposition gene 1, BRCA1, and the Near BRCA1 2 (NBR2) gene. In HeLa cells, quantitative chromatin immunoprecipitation assays indicated that MBD2 is associated with the methylated region, while MeCP2 and MBD1 were not detected at this locus. MBD2 depletion (approximately 90%), mediated by a transgene expressing a small interfering RNA (siRNA), did not induce MeCP2 or MBD1 binding at the methylated area. Furthermore, the lack of MBD2 at the BRCA1-NBR2 CpG island is associated with an elevated level of NBR2 transcripts and with a significant reduction of induced-DNA-hypomethylation response. In MBD2 knockdown cells, transient expression of a Mbd2 cDNA, refractory to siRNA-mediated decay, shifted down the NBR2 mRNA level to that observed in unmodified HeLa cells. Variations in MBD2 levels did not affect BRCA1 expression despite its stimulation by DNA hypomethylation. Collectively, our data indicate that MBD2 has specific targets and its presence at these targets is indispensable for gene repression.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.